Veradermics reported net income of -$23.87M for the quarter ended Jun 2026. This income statement covers 6 quarters of results from Dec 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2024 | Mar2025 | Jun2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 0.74M | 0.74M | 0.75M | 0.75M | 22.70M | 41.78M |
| Operating items | ||||||
| Research & DevelopmentR&D | 11.45M | 14.33M | 20.93M | 18.61M | ||
| Selling, General & AdministrativeSG&A | 1.47M | 1.74M | 8.94M | 10.95M | ||
| Operating ExpensesOpex | 12.91M | 16.07M | 29.86M | 29.55M | ||
| Operating IncomeOp. Inc | -12.91M | -16.07M | -29.86M | -29.55M | ||
| EBIT | -12.91M | -16.07M | -29.86M | -29.55M | ||
| Non-operating items | ||||||
| Interest & Investment IncomeInt & Inv Inc | 0.48M | 0.10M | 2.48M | 4.84M | ||
| Other Non Operating IncomeOther Non Op Inc. | 0.03M | 0.33M | 0.15M | 1.21M | ||
| Non Operating IncomeNon Op. Inc. | 0.52M | 0.43M | 2.63M | 6.05M | ||
| Net income details | ||||||
| EBT | -12.40M | -15.64M | -27.23M | -23.50M | ||
| Profit After TaxPAT | -12.40M | -18.01M | -27.23M | -23.87M | ||
| Income from Continuing OperationsIncome (Continuing) | -12.40M | -15.64M | -27.23M | -23.50M | ||
| Consolidated Net IncomeConsol Net Inc. | -12.40M | -15.64M | -27.23M | -23.50M | ||
| Income towards Parent CompanyParent Net Inc | -12.40M | -15.64M | -27.23M | -23.50M | ||
| Net Income towards Common StockholdersNet Income | -14.58M | -18.01M | -30.01M | -23.50M | ||
| Additional items | ||||||
| EPS (Basic) | -19.79 | -24.19 | -1.32 | -0.58 | ||
| EPS (Diluted) | -19.79 | -24.19 | -1.32 | -0.58 | ||
| Shares Outstanding | 0.74M | 0.74M | 0.74M | 0.74M | 22.70M | 40.44M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 0.74M | 0.74M | 0.74M | 0.74M | 22.70M | 40.44M |
| EBITDA | -12.91M | -16.07M | -29.86M | -29.55M |